JP4238031B2 - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP4238031B2
JP4238031B2 JP2002570736A JP2002570736A JP4238031B2 JP 4238031 B2 JP4238031 B2 JP 4238031B2 JP 2002570736 A JP2002570736 A JP 2002570736A JP 2002570736 A JP2002570736 A JP 2002570736A JP 4238031 B2 JP4238031 B2 JP 4238031B2
Authority
JP
Japan
Prior art keywords
mouse
protein
cil
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002570736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502314A (ja
JP2005502314A5 (enExample
Inventor
アシュマン，クレア
クロウ，ジェームズ，スコット
エリス，ジョナサン，ヘンリー
ルイス，アラン，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005502314A publication Critical patent/JP2005502314A/ja
Publication of JP2005502314A5 publication Critical patent/JP2005502314A5/ja
Application granted granted Critical
Publication of JP4238031B2 publication Critical patent/JP4238031B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002570736A 2001-03-03 2002-03-01 ワクチン Expired - Fee Related JP4238031B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (3)

Publication Number Publication Date
JP2005502314A JP2005502314A (ja) 2005-01-27
JP2005502314A5 JP2005502314A5 (enExample) 2005-12-22
JP4238031B2 true JP4238031B2 (ja) 2009-03-11

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002570736A Expired - Fee Related JP4238031B2 (ja) 2001-03-03 2002-03-01 ワクチン

Country Status (18)

Country Link
US (3) US20050260216A1 (enExample)
EP (1) EP1368477A1 (enExample)
JP (1) JP4238031B2 (enExample)
KR (1) KR20030081490A (enExample)
CN (1) CN1543504A (enExample)
AU (1) AU2002233560B2 (enExample)
BR (1) BR0207819A (enExample)
CA (1) CA2439628A1 (enExample)
CZ (1) CZ20032373A3 (enExample)
GB (1) GB0105360D0 (enExample)
HU (1) HUP0303372A3 (enExample)
IL (1) IL157498A0 (enExample)
MX (1) MXPA03007915A (enExample)
NO (1) NO20033882L (enExample)
NZ (1) NZ527873A (enExample)
PL (1) PL365066A1 (enExample)
WO (1) WO2002070711A1 (enExample)
ZA (1) ZA200306647B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77152C2 (en) * 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
EP1539232A1 (en) * 2002-09-12 2005-06-15 Pharmexa A/S Immunization against autologous ghrelin
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
EP1594533B1 (en) * 2003-01-31 2012-04-11 Celldex Research Corporation Antibody vaccine conjugates and uses therefor
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1767216B1 (en) * 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター及びその使用
BRPI0820270A2 (pt) * 2007-11-07 2015-06-16 Celldex Therapeutics Inc Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2022212600A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
AU3382595A (en) * 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
ES2289751T3 (es) * 1995-02-20 2008-02-01 The Walter And Eliza Hall Institute Of Medical Research Moleculas inmunorreactivas e inmunoterapeuticas que interaccionan en sujetos con diabetes mellitus insulinodependientes (dmid).
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
EP1071333A4 (en) * 1998-03-20 2005-02-23 Genzyme Corp INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENS
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
AU1599301A (en) * 1999-11-11 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13

Also Published As

Publication number Publication date
KR20030081490A (ko) 2003-10-17
US20050186209A1 (en) 2005-08-25
GB0105360D0 (en) 2001-04-18
HUP0303372A2 (hu) 2004-01-28
NO20033882D0 (no) 2003-09-02
CN1543504A (zh) 2004-11-03
MXPA03007915A (es) 2003-12-04
NZ527873A (en) 2005-12-23
JP2005502314A (ja) 2005-01-27
CA2439628A1 (en) 2002-09-12
NO20033882L (no) 2003-10-31
BR0207819A (pt) 2004-03-02
EP1368477A1 (en) 2003-12-10
US20050260216A1 (en) 2005-11-24
IL157498A0 (en) 2004-03-28
PL365066A1 (en) 2004-12-27
HUP0303372A3 (en) 2008-06-30
CZ20032373A3 (cs) 2004-01-14
AU2002233560B2 (en) 2006-09-07
WO2002070711A1 (en) 2002-09-12
US20030194391A1 (en) 2003-10-16
ZA200306647B (en) 2004-11-26

Similar Documents

Publication Publication Date Title
JP4238031B2 (ja) ワクチン
AU2002233560A1 (en) Vaccine
KR100671036B1 (ko) 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
ES2527410T3 (es) Inmunoconjugados de miostatina para el tratamiento de atrofia muscular progresiva
CN116023510B (zh) 双佐剂重组带状疱疹疫苗
JP6987744B2 (ja) 虫刺され過敏症の治療
CZ9903657A3 (cs) Modifikované molekuly TNFalfa, DNA kódující takové modifikované molekuly TNFalfa a vakcíny obsahující uvedené modifikované molekuly TNFalfa
KR19990022654A (ko) 보호 면역 반응을 증강시키는 방법
JP2005503320A (ja) ＣｐＧ−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法
US20060147417A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2022513452A (ja) 融合によって修飾されたｃｍｖのウイルス様粒子
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
KR101101004B1 (ko) 신규한 펩티드 및 그들의 치료 용도
JP2006503018A (ja) ワクチン
MÉVÉLEC et al. Mapping of B epitopes in GRA4, a dense granule antigen of Toxoplasma gondii and protection studies using recombinant proteins administered by the oral route.
CA2421274A1 (en) Method for down-regulating ige
JP2019515957A (ja) イヌアトピー性皮膚炎の治療
US20130122026A1 (en) Dna vaccine for alzheimer's disease
JPWO2018088507A1 (ja) マラリアワクチン
JP2005529091A (ja) エオタキシン伝達炎症状態の処置および予防方法および組成物
WO2025017537A1 (en) Active immunization for treating atopic dermatitis
KR20060010730A (ko) 염증 상태를 치료하고 예방하기 위한 방법과 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081219

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111226

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees